More specifically, because one of the main differences between our model and for instance chronic treatment of adult animals with mTOR inhibitors or virally-mediated alterations in mTORC1 pathway, is the developmental period and the length of time during which S6K1 activity is altered, an interesting first step would be to determine whether there is a critical time window for the involvement of S6K1 in driving anxiety-like behavior. The gene discussed is MTOR; the disease is Anxiety.